ES2174970T3 - Mezcla propelente para formulacion de aerosol. - Google Patents

Mezcla propelente para formulacion de aerosol.

Info

Publication number
ES2174970T3
ES2174970T3 ES95941077T ES95941077T ES2174970T3 ES 2174970 T3 ES2174970 T3 ES 2174970T3 ES 95941077 T ES95941077 T ES 95941077T ES 95941077 T ES95941077 T ES 95941077T ES 2174970 T3 ES2174970 T3 ES 2174970T3
Authority
ES
Spain
Prior art keywords
aerosol formulation
propellent
mix
propellant
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95941077T
Other languages
English (en)
Inventor
Andrew Sapsford
Andrew Patrick Savage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2174970T3 publication Critical patent/ES2174970T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

ESTA INVENCION SE REFIERE A FORMULACIONES DE AEROSOL PARA UTILIZAR EN LA ADMINISTRACION DE MEDICAMENTOS POR INHALACION, Y EN ESPECIAL EN UNA FORMULACION DE AEROSOL FARMACEUTICO QUE INCLUYE (A) 1,1,1,2-TETRAFLUOROETANO O 1,1,1,2,3,3,3-HEPTAFLUORON-PROPANO O MEZCLAS DE LO ANTERIOR COMO PROPELENTE, (B) 1,1,2,2,3-PENTAFLUOROPROPANO COMO COPROPELENTE; Y (C) UN MEDICAMENTO PARTICULADO. TAMBIEN SE DESCRIBE UN METODO PARA TRATAR TRASTORNOS RESPIRATORIOS QUE SUPONE LA ADMINISTRACION MEDIANTE INHALACION DE UNA CANTIDAD EFECTIVA DE UNA FORMULACION EN AEROSOL FARMACEUTICO COMO SE DEFINE.
ES95941077T 1994-12-10 1995-12-08 Mezcla propelente para formulacion de aerosol. Expired - Lifetime ES2174970T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9425160.0A GB9425160D0 (en) 1994-12-10 1994-12-10 Medicaments

Publications (1)

Publication Number Publication Date
ES2174970T3 true ES2174970T3 (es) 2002-11-16

Family

ID=10765889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95941077T Expired - Lifetime ES2174970T3 (es) 1994-12-10 1995-12-08 Mezcla propelente para formulacion de aerosol.

Country Status (9)

Country Link
US (2) US6153173A (es)
EP (1) EP0789557B1 (es)
JP (1) JPH10510521A (es)
AT (1) ATE216575T1 (es)
AU (1) AU4260496A (es)
DE (1) DE69526517T2 (es)
ES (1) ES2174970T3 (es)
GB (1) GB9425160D0 (es)
WO (1) WO1996018384A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
ATE199565T1 (de) * 1991-12-03 2001-03-15 Us Environment Kältemittelzusammensetzung sowie verfahren zu deren benutzung
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
DE69218455T2 (de) * 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzungen für arzneimittelsuspensionen
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
GB9620187D0 (en) † 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
WO1998037164A1 (en) * 1997-02-24 1998-08-27 Alliedsignal Inc. Azeotrope-like compositions of pentafluoropropane and tetrafluoroethane
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6235265B1 (en) 1998-10-28 2001-05-22 Alliedsignal Inc. Evaporative coolant for topical anesthesia comprising hydrofluorocarbons and/or hydrochlorofluorocarbons
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
ATE233084T1 (de) * 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
GB9918626D0 (en) * 1999-08-07 1999-10-13 Glaxo Group Ltd Valve
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
ES2290038T3 (es) * 2000-05-11 2008-02-16 Alliedsignal Inc. Fluido refrigerante evaporativo que comprende hidrofluorocarbonos.
CZ303833B6 (cs) 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
DE60335401D1 (de) * 2002-09-06 2011-01-27 Philip Morris Usa Inc Aerosolerzeugungsvorrichtungen und verfahren zur erzeugung von aerosolen mit gesteuerten teilchengrössen
CN1700934B (zh) * 2002-09-06 2011-08-03 菲利普莫里斯美国公司 液体气溶胶制剂和用于制备气溶胶的气溶胶产生装置及方法
WO2004060260A2 (en) * 2002-12-18 2004-07-22 Glaxo Group Limited Drug delivery system with vented mouthpiece
US20040223918A1 (en) * 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
US20070039635A1 (en) * 2005-08-19 2007-02-22 Honeywell International Inc. Gas jet apparatus and method
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
EP2265309B1 (en) 2008-03-17 2015-12-16 Discovery Laboratories, Inc. Ventilation circuit adaptor and proximal aerosol delivery system
CA2683353C (en) 2008-10-22 2015-12-15 Trudell Medical International Modular aerosol delivery system
CN111297802A (zh) * 2018-12-12 2020-06-19 成都一平医药科技发展有限公司 一种用于抗炎及抗菌的组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
NZ243061A (en) * 1991-06-10 1993-09-27 Schering Corp Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
EP0595937B1 (en) * 1991-07-22 1995-08-23 E.I. Du Pont De Nemours And Company Use of 1,2,2,3,3-pentafluoropropane
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US5278196A (en) * 1993-03-25 1994-01-11 Great Lakes Chemical Corp. Hydrofluorocarbon compositions as blowing agents for cellular plastics
DK0735884T3 (da) * 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide

Also Published As

Publication number Publication date
US6153173A (en) 2000-11-28
WO1996018384A1 (en) 1996-06-20
ATE216575T1 (de) 2002-05-15
AU4260496A (en) 1996-07-03
DE69526517D1 (de) 2002-05-29
US6309624B1 (en) 2001-10-30
JPH10510521A (ja) 1998-10-13
GB9425160D0 (en) 1995-02-08
DE69526517T2 (de) 2002-10-31
EP0789557B1 (en) 2002-04-24
EP0789557A1 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
ES2174970T3 (es) Mezcla propelente para formulacion de aerosol.
MY109758A (en) Aerosol formulations of use for the administration of medicaments by inhalation
GB9426252D0 (en) Pharmaceutical composition
DK0616525T3 (da) Medikamenter
DK0656207T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
CA2125666A1 (en) Medicaments
MY108748A (en) Medicaments
BG105033A (en) Pharmaceutical formulations for aerosols with two or more active substances
PH27594A (en) Medicaments for the treatment of asthma and other respiratory disorders
BR9712125A (pt) Formulação farmaucêutica em aerosol, uso de uma mistura, produto farmacêutico, e, processo de administração de budesonida a um paciente
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
TH13643EX (th) สูตรผสมรูปแบบละอองลอยทางเภสัชกรรมซึ่งมีสารรักษาโรคและตัวผลักดันชนิดไฮโดรฟลูโอโรคาร์บอน
MY111155A (en) Medicaments

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 789557

Country of ref document: ES